LABORIE Medical Technologies Inc.
Please contact Sales at: (212) 520-2765 or email [email protected]
Latest From LABORIE Medical Technologies Inc.
Immix collaborates with Israeli research institutions on BCMA-targeted CAR-T therapy. NeoImmuneTech/NIAID alliance could pave way for “animal rule” approval in acute radiation syndrome.
Medtech Insight recorded 17 merger or acquisition deals in March, a rise from the nine deals recorded last month and in the same period last year. It was a busy month for Boston Scientific, which racked up two acquisitions, paying $460m for urology device maker NxThera and an undisclosed price for endoscopy firm EMcision.
The deal adds Cogentix' Urgent PC neuromodulation system for urinary incontinence, PrimeSight cystoscopy system, and Macroplastique soft-tissue bulking agent to treat female stress urinary incontinence to Laborie's range of urology and gynecology products.
M&A deal activity waned in March, with a total of 9 deals completed in the month, down from 12 in February and 17 in March 2016. This third month brought the total number of deals for Q1 2017 to 33, a significant year-on-year decline compared to 51 in the first quarter of 2016.
- Diagnostic Equipment & Supplies
- Diagnostic Imaging Equipment & Supplies
- Other Names / Subsidiaries
- Camden Merger Sub, Inc.
- Cogentix Medical, Inc.
- Investor AB
- LM US Parent, Inc.
- Patricia Industries
- Pelvalon, Inc.
- Clinical Innovations LLC
- GI Supply
All set! This article has been sent to firstname.lastname@example.org.
All fields are required. For multiple recipients, separate email addresses with a semicolon.